What NOVACYT does

Novacyt S.A. is an international molecular diagnostics group incorporated in France in 2006 and operationally headquartered in Manchester, UK, with 101–250 employees and listings on Euronext Growth Paris and the London Stock Exchange's AIM market (ticker: NCYT). The group develops, manufactures, and commercialises molecular assays and instrumentation for sample-to-result workflows across three sectors: human health (clinical diagnostics), animal health, and environmental testing. The portfolio is organised across three operating brands: Primerdesign, providing open-platform qPCR assays and genesig q16/q32 instruments for pathogen detection and surveillance; Yourgene Health, providing NIPT workflows (IONA Nx, Sage 32), Ranger Technology-powered DNA size selection instruments (LightBench, LightBench Discover), automated DNA extraction (MagBench), pharmacogenomic tests (DPYD genotyping assay), and reproductive health clinical screening assays; and Southern Cross Diagnostics, an Australia/New Zealand-focused distribution platform acquired in March 2026.

The group's revenue model combines one-time product sales of assays and instruments, professional services revenue from NIPT testing delivered through Yourgene Genomic Services' Manchester laboratory, and transaction-based distribution revenue from regional subsidiaries and channel partners. Customer segments include clinical diagnostic laboratories, genomic research institutions, veterinary and animal health laboratories, and environmental testing operations, with go-to-market executed through direct regional offices in the UK, France, US, Canada, and Singapore, supplemented by distributor partnerships in Morocco, Colombia, and Australia/NZ. Notable product differentiators include the IVDR-certified DPYD genotyping assay (first pharmacogenomics test of its kind to conform to EU IVDR), Ranger Technology's patented machine-vision control of gel electrophoresis, and PacBio-compatible LightBench instruments for long-read sequencing workflows.

FY2025 group revenue was £20.0 million with 4% organic growth, EBITDA loss of £7.8 million, and net loss reduced to £22.9 million from £42.0 million the prior year. The group ended 2025 with £11 million in cash, completed the Southern Cross Diagnostics acquisition in March 2026 (funded via a €784,736 oversubscribed rights issue), and in June 2026 launched a workforce reduction consultation targeting approximately 40% of its 230 employees to reduce annual cash burn by up to £4 million.

Name

NOVACYT

Legal name

Novacyt S.A.

Website

https://novacyt.com

Company type

Public

Founded year

2006

Operating status

Operating

Headcount range

101–250 employees

Short description

Novacyt is an international molecular diagnostics group developing qPCR assays, NIPT workflows, Ranger Technology-powered DNA size selection instruments, and IVDR-certified pharmacogenomic tests, serving clinical laboratories, healthcare providers, and research institutions across Europe, the Americas, Asia-Pacific, and Oceania.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD)

akta.pro secondary industries

Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening) (HLAAALAJ), Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI), Molecular Diagnostics (PCR/qPCR, NGS-based assays) (HLAAALAA), Genetic & Prenatal Testing Laboratories (HLAFAMAH), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF)

Keywords

• Molecular diagnostics
• QPCR assay kits
• NIPT workflows
• DNA size selection
• Pharmacogenomic testing

Headquarters

HQ city

Vélizy-villacoublay

HQ country

France

HQ region

Europe

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Clinical Diagnostics Products: Sale of molecular diagnostic assays and instruments for human health applications including reproductive health (NIPT, cystic fibrosis), precision medicine (DPYD genotyping), and infectious diseases testing.
2. Research Tools and Assays: Primerdesign provides qPCR assays and workflows for research use in human health, agriculture, veterinary, and environmental sectors. Includes custom development services and OEM-ready end-to-end qPCR kits.
3. NIPT Testing Services: Yourgene Genomic Services provides NIPT screening services through laboratory testing including IONA Care+ comprehensive screening menu. Service results delivered within 3-5 working days.
4. Distribution Revenue: Southern Cross Diagnostics distributes diagnostic and life science products in Australian and New Zealand markets, contributing approximately £6.7 million in annual revenue.

Go-to-market motion3 records

Distribution channels5 records

Marketing channels5 records

Core offering

NOVACYT develops, manufactures, and commercializes molecular diagnostic assays, instruments, and services across three operating brands. Primerdesign supplies open-platform qPCR assays and genesig instruments for human health, animal health, agriculture, and environmental pathogen detection. Yourgene Health provides non-invasive prenatal testing (NIPT) NGS workflows (IONA Nx and Sage 32), Ranger Technology-powered DNA size selection instruments (LightBench), the IVDR-certified DPYD genotyping assay for chemotherapy safety, and clinical reproductive health assays. Southern Cross Diagnostics distributes human diagnostics and life science products in Australia and New Zealand.

Product overview

NOVACYT is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services focused on genomic medicine delivery, organized across three business segments: Clinical (in vitro diagnostic products and services), Instrumentation (sample preparation and PCR platforms), and Research Use Only (life sciences qPCR tools). The portfolio is structured around three core brands: Primerdesign provides open-platform qPCR assays and instruments (genesig product line) for human health, animal health, agriculture, veterinary, and environmental applications; Yourgene Health offers NIPT solutions (IONA Nx and Sage 32 workflows), Ranger Technology-powered DNA size selection instruments (LightBench, LightBench Discover), automated DNA extraction (MagBench), pharmacogenomics (Yourgene Insight DPYD assay), and clinical reproductive health assays; and Southern Cross Diagnostics distributes human diagnostics and life science products in Australia and New Zealand. The company also offers whole genome sequencing (WGS) and whole exome sequencing (WES) pharmaceutical research services under its Research Use Only segment.

Differentiator

Problem solved

Functional benefit

Brands

• Primerdesign: Real-time PCR assays and qPCR products for research to surveillance applications. Provides custom development services and solutions for human health, animal health, environmental testing and food safety integrity.
• Yourgene Health
• Southern Cross Diagnostics

Products and services

• Primerdesign genesig qPCR Assays and Workflows Ready-to-deploy, open-platform qPCR assays and integrated sample-to-result workflows delivering high-performance molecular detection across a broad pathogen menu, including customizable assays, OEM-ready end-to-end qPCR kits, and custom development services for research and surveillance applications.
• genesig q16 and q32 Real-Time PCR Instruments Quantitative real-time PCR instruments forming part of the genesig workflow portfolio for rapid pathogen detection and outbreak surveillance across human health, animal health, agriculture, and environmental testing.
• genesig Easy_oys Norovirus Detection Kit A quantitative PCR kit for rapid, onsite detection and quantification of Norovirus GI and GII pathogens in oyster tissue per ISO 15216 guidelines. Includes extraction reagents, qPCR kit, and compatible genesig q16 instrument, delivering results in four hours.
• IONA Nx NIPT Workflow A complete CE-IVD next-generation sequencing workflow enabling laboratories to offer in-house non-invasive prenatal testing for trisomy 21, 18, 13, sex chromosome aneuploidies, and microdeletions using cell-free placental DNA from maternal blood.
• Sage 32 NIPT Workflow A next-generation sequencing NIPT workflow delivering results in three days, screening for trisomy 21, 18, 13, rare autosomal aneuploidies, sex chromosome aneuploidies, and clinically relevant microdeletions.
• IONA Care+ NIPT Service A fully comprehensive non-invasive prenatal screening service offering trisomies, sex chromosome aneuploidies, and clinically relevant microdeletion syndromes (DiGeorge, Prader-Willi, Angelman, 1p36 deletion, Cri-du-Chat, Wolf-Hirschhorn), delivered through Yourgene Genomic Services' Manchester laboratory.
• LightBench Instrument An automated electrophoresis instrument powered by Ranger Technology delivering precise and accurate target enrichment of DNA libraries for human genomic applications and long-read sequencing, qualified by PacBio for use with PacBio Revio and Vega systems.
• LightBench Discover A 3-in-1 high-precision instrument integrating large fragment analytics (up to 150 kilobases), DNA size selection powered by Ranger Technology, and fluorometric quantification in a single benchtop system for genomic research labs conducting long-read HiFi sequencing.
• MagBench Automated DNA Extraction Instrument and Kit A bench-top robotic cell-free DNA extraction workstation with touchscreen interface, pre-sealed cartridges, and single-use tip disposal, optimized for the Sage 32 NIPT Workflow and available to clinical labs in Asia-Pacific and the Middle East.
• Yourgene Insight DPYD Genotyping Assay (19-variant) A pharmacogenomics PCR assay identifying cancer patients with Dihydropyrimidine Dehydrogenase (DPD) deficiency to enable safer 5-Fluorouracil chemotherapy. Enhanced 19-variant version per updated AMP/ACMG guidelines. Class C in vitro medical device under IVDR with IVDR certification achieved.
• Yourgene Health Clinical Screening Assays A portfolio of PCR-based clinical screening assays supporting the reproductive lifecycle, including cystic fibrosis testing, aneuploidy analysis, pregnancy loss screening, male factor infertility testing, and thrombosis risk assessment.

Quantifiable outcome

• 19 genetic variants detected in enhanced DPYD assay, up from 6 in original 2019 test
• +5 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability4 records

Feature5 records

Partnerships

Five partnerships are on record, tiered core and minor.

• GenetixcoreChannel Partner/ Reseller/ Distributor · 2 October 2024First NIPT workflow installation in Colombia using IONA Nx NIPT Workflow branded as NipTest. Genetix operates as local distributor providing NIPT services, reducing turnaround times and shipping problems compared to sending samples to USA for testing.
• Shellfish Association of Great Britain and Oyster FarmersminorStrategic or Co-development Partner · 25 June 2024Collaborative development of genesig Easy_oys Detection Kit for Norovirus detection in oysters. Partnership involved oyster farmers and industry association in product development to ensure the qPCR workflow meets practical needs for on-site shellfish safety testing.
• PacBiocoreTechnology or Integration · 17 November 2023PacBio Compatible Partner program collaboration. Yourgene Health's LightBench instrument qualified for PacBio SMRTbell library size selection, enabling optimized long-read HiFi sequencing on PacBio Revio and Vega systems. Collaboration includes joint technical note publication and marketing through PacBio's compatible partners webpage.
• HudsonAlpha Institute for Biotechnology (The CoLab)minorStrategic or Co-development Partner · 17 November 2023Collaborator on LightBench Discover development and testing. The CoLab at HudsonAlpha deployed prototype instruments to gather customer feedback, develop protocols, and run real-world samples for performance assessment.
• Laboriad (Centre de Biologie Riad)coreChannel Partner/ Reseller/ Distributor · 9 November 2023First NIPT platform installation in Morocco enabling Laboriad to offer non-invasive prenatal testing locally branded as COSY test. Novacyt provides IONA test technology while Laboriad operates local laboratory service, expanding access to prenatal screening in Morocco and surrounding regions.

Scale indicators16 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• BGI Genomics: BGI Genomics is a global NIPT provider operating the NIFTY test and a broader molecular diagnostics portfolio. Direct peer to Novacyt in prenatal screening and a key competitor in international markets where Novacyt is expanding with channel partners.
• NeoGenomics: NeoGenomics provides clinical molecular diagnostics and oncology testing services, including liquid biopsy and tumor profiling. Comparable to Novacyt's clinical diagnostics laboratory services and DPYD pharmacogenomics positioning in oncology workflows.
• Natera: Natera is a direct NIPT competitor offering the Panorama prenatal screening test along with a broader molecular diagnostics portfolio. Directly comparable to Novacyt's IONA Nx and Sage 32 NIPT workflows and Yourgene Genomic Services laboratory testing offering.
• QIAGEN: QIAGEN provides sample-preparation technologies, qPCR assays, and IVD molecular diagnostic kits across reproductive health, infectious disease, and oncology. Comparable to Novacyt across Primerdesign qPCR assays, Yourgene DNA size-selection instrumentation, and IVDR-certified clinical assays.

Broad incumbents

• Hologic: Hologic's diagnostics division offers the Panther molecular diagnostics platform and women's health assays including NIPT and infectious disease. Comparable to Novacyt's clinical diagnostics portfolio, particularly in reproductive health and women's health IVD.
• Eurofins Scientific: Eurofins operates a global network of clinical and genomic testing laboratories alongside a diagnostics products business. Comparable to Novacyt's Yourgene Genomic Services NIPT laboratory services and its distribution-style operating model through Southern Cross Diagnostics.
• Revvity: Revvity (formerly PerkinElmer) provides a broad life sciences and diagnostics portfolio spanning reproductive health screening, genomics, and immunodiagnostics. Comparable to Novacyt in reproductive health IVD and applied genomics workflows.
• Bio-Rad Laboratories: Bio-Rad supplies molecular biology tools, qPCR systems (CFX), and clinical diagnostics products. Comparable to Novacyt's Primerdesign genesig qPCR instrument and reagent portfolio across research and applied diagnostics use cases.
• Myriad Genetics: Myriad Genetics provides molecular diagnostic tests across hereditary cancer, reproductive health, and pharmacogenomics. Comparable to Novacyt's DPYD assay positioning in chemotherapy-safety pharmacogenomics and reproductive-health screening menu.

Emerging players

• Oxford Nanopore Technologies: Oxford Nanopore develops long-read sequencing platforms with integrated sample-prep workflows. Comparable to Novacyt in the long-read sequencing adjacency and a potential competitor to LightBench Discover in size-selection and fragment-analysis workflows.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/novacytgroup

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries4 records

Funding overview

Funding rounds8 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A6 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NOVACYT